Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VX-222 + telaprevir
- Development stage
- Unknown
- Lead developer
- Vertex
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VX-222 + telaprevir is an investigational oral combination of two direct-acting antivirals developed for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection. **VX-222** is a small molecule non-nucleoside inhibitor that selectively targets the HCV NS5B polymerase, a key enzyme necessary for viral RNA replication. **Telaprevir** is a small molecule inhibitor of the HCV NS3/4A protease, another essential viral enzyme that cleaves the viral polyprotein, enabling viral maturation and replication. Administered together, these agents act on distinct steps of the viral lifecycle to suppress HCV replication more effectively. The combination has been tested in various multi-drug regimens (including with pegylated interferon and ribavirin) in phase 2 trials.
- Brand names
- IncivekIncivo
- Other names
- telaprevir + VX-222
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on VX-222 + telaprevir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VX-222 + telaprevir.